Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | triose-phosphate isomerase TPI-II | 0.0091 | 0.7857 | 1 |
Leishmania major | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0073 | 0.5371 | 0.5371 |
Loa Loa (eye worm) | triosephosphate isomerase | 0.0091 | 0.7857 | 0.7857 |
Mycobacterium ulcerans | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0107 | 1 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0107 | 1 | 1 |
Trypanosoma cruzi | triosephosphate isomerase, putative | 0.0091 | 0.7857 | 1 |
Mycobacterium tuberculosis | Probable triosephosphate isomerase Tpi (TIM) | 0.0091 | 0.7857 | 1 |
Trichomonas vaginalis | triosephosphate isomerase, putative | 0.0091 | 0.7857 | 1 |
Plasmodium vivax | triosephosphate isomerase, putative | 0.0091 | 0.7857 | 1 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.007 | 0.4982 | 0.6129 |
Schistosoma mansoni | hypothetical protein | 0.0073 | 0.5371 | 0.6836 |
Trichomonas vaginalis | triosephosphate isomerase, putative | 0.0091 | 0.7857 | 1 |
Mycobacterium leprae | Probable triosephosphate isomerase Tpi (TIM) | 0.0091 | 0.7857 | 1 |
Schistosoma mansoni | triosephosphate isomerase | 0.0037 | 0.0429 | 0.0546 |
Toxoplasma gondii | triose-phosphate isomerase TPI-I | 0.0091 | 0.7857 | 1 |
Echinococcus granulosus | proteasome prosome macropain | 0.007 | 0.4982 | 0.634 |
Giardia lamblia | Triosephosphate isomerase, cytosolic | 0.0091 | 0.7857 | 1 |
Trypanosoma brucei | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.007 | 0.4982 | 0.6129 |
Loa Loa (eye worm) | hypothetical protein | 0.0107 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | triosephosphate isomerase | 0.0091 | 0.7857 | 0.5 |
Plasmodium falciparum | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Echinococcus multilocularis | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.007 | 0.4982 | 0.4982 |
Schistosoma mansoni | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0073 | 0.5371 | 0.5371 |
Chlamydia trachomatis | triosephosphate isomerase | 0.0091 | 0.7857 | 0.5 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.007 | 0.4982 | 0.634 |
Brugia malayi | Proteasome A-type and B-type family protein | 0.007 | 0.4982 | 0.4982 |
Brugia malayi | triosephosphate isomerase | 0.0091 | 0.7857 | 0.7857 |
Treponema pallidum | triosephosphate isomerase | 0.0091 | 0.7857 | 0.5 |
Echinococcus granulosus | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.007 | 0.4982 | 0.634 |
Entamoeba histolytica | triosephosphate isomerase | 0.0091 | 0.7857 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | = 24 % | Growth inhibition of human MCF7 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 51 % | Growth inhibition of human HeLa cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 54 % | Growth inhibition of human IMR32 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 61 % | Growth inhibition of human A549 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 62 % | Growth inhibition of human THP1 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 62 % | Growth inhibition of human PC3 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
GI (functional) | = 64 % | Growth inhibition of human OVCAR5 cells at 50 uM after 48 hrs by sulpharhodamine B assay | ChEMBL. | 22245048 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.